ClinicalTrials.gg
RecruitingNCT06104150TELEUpdated Sep 12, 2025

Erythrocyte Transport of Lactate During Exercise (TELE Project)

An interventional study of Intervallic submaximal exercise test in Energy Metabolism, sponsored by Technical University of Madrid. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Technical University of Madrid · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Feb 2020, registered Oct 2023).
  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.

Planned enrollment
261st of 539
84 · median 80
Started
2020
with 28 others
No phase
515 of 597
125 open now
Primary completion
2027-06
later than 138 of 183 live
Registered
360th of 597
by date

Among the 597 studies in Motor Activity with a site in Spain, this one is the 261st largest by planned enrollment of the 539 interventional ones that give a count, is one of 29 that started in 2020, is one of 515 with no phase, reaches primary completion later than 138 of the 183 other live ones, and was the 360th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 597 studies in Motor Activity with a site in Spain, or all of them as a file.
02

Study summary

The goals of this clinical trial are:

  1. to study lactate kinetic between plasma and erythrocytes during an intervallic exercise and its subsequent recovery, considering the blood pH, the genotype for the T1470A polymorphism of the SLC16A1 gene (rs1049434), and the amount of MCT1 in erythrocytes membrane;
  2. to analyze the levels of MCT1 in the erythrocytes membrane according to training status and genotype for the T1470A polymorphism of SLC16A1 (rs1049434).

For this, the project will have two phases:

  • In phase I, trained participants will perform one maximal incremental test and one intervallic submaximal test with a final active recovery.
  • Phase II, levels of the MCT1 protein in the erythrocyte membrane will be quantified from trained and sedentary participants.
Read the detailed description

Introduction

Lactate is the end product of glycolysis and has the capacity to be transported from one cell to another, performing numerous functions. This transport is mainly through several monocarboxylate transporters (MCT). The most predominant is MCT1, which transfers lactate bidirectionally depending on the lactate concentration and pH on each side of the membrane. MCT1 is ubiquitous, being present in most human tissues like the erythrocyte membrane, indicating that these cells are capable of carrying lactate throughout the bloodstream. Some studies have described lactate kinetics between the different blood compartments (erythrocyte-plasma) during incremental and steady-state exercises, but not during intermittent exercise and/or recovery after exercise. Moreover, several studies have observed that the function of MCT1 is conditioned by the presence of a genetic variant: the T1470A polymorphism (rs1049434), which involves a substitution of aspartic acid for glutamic acid at position 490 of the protein. Data suggest that an AA (Glu/Glu) genotype for this single nucleotide polymorphism (or SNP) leads to a higher lactate transport capacity than the TT (Arg/Arg) profile. However, no study has analyzed if this SNP directly affects erythrocyte MCT1 function or content Therefore, the two general objectives of this clinical trial are:

  1. to study lactate kinetic between plasma and erythrocytes during an intervallic exercise and its subsequent recovery, considering the blood pH, the genotype for the T1470A polymorphism of the SLC16A1 gene (rs1049434), and the amount of MCT1 in erythrocytes membrane;
  2. to analyze the levels of MCT1 in the erythrocytes membrane according to training status and genotype for the T1470A polymorphism of SLC16A1 (rs1049434).

Procedures

The study will be divided into two phases, each of which will be primarily oriented toward achieving one of two general objectives:

  • Phase I: Focused primarily on the study of lactate kinetics between blood compartments during exercise.
  • Phase II: Focused primarily on the analysis of the amount of MCT1 in the erythrocyte membrane.

For both phases, volunteers will be informed and sign an informed consent form before a blood sample is taken for genotyping. Once the genotype is known, only those participants with AA or TT genotype will be selected.

The tests that will be performed throughout Phase I will be the following:

  • Once participants with the genotypes AA and TT are selected, they will perform a step incremental test until exhaustion to determine the first and second lactate threshold. These thresholds will be determined by measuring lactate concentration from capillary blood samples from the earlobe.
  • Finally, an intervallic exercise protocol will be performed starting with 1 min rest followed by a 5 min warm up at an intensity equal to 80% of the first lactate threshold. This is followed by 4 sets of 1 min 30 sec at an intensity 20% above the second lactate threshold, with recovery intervals of 5 min at 80% of the first lactate threshold. After the 4 sets, a final recovery of 20 min at 80% of the first lactate threshold will be performed. During this test, capillary blood samples from the earlobe and venous blood samples from the forearm will be analyzed for lactate concentration.

The procedure for the Phase II will be the following:

  • Once participants with the genotype AA and TT are selected, venous blood will be extracted from their forearm at rest.
  • Physical activity levels from all the participants will be quantified using the International Physical Activity Questionnaire (IPAQ).
  • Analysis of the erythrocyte MCT1 protein content by flow cytometry will be performed from the venous blood samples.
03

Conditions studied

  • Energy Metabolism

Browse trials for

Keywords

  • lactate kinetics
  • MCT1
  • erythrocyte lactate
  • T1470A polymorphism
  • exercise
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 25 kg/m2
  • Not smoker
  • In the case of trained participants: training at least 5 hours/week, of which at least 3 must be aerobic/anaerobic endurance training. Presentation of a medical certificate attesting to their medical fitness (capability) to perform intense physical exercise.
  • In the case of sedentary participants, less than 1 day of training per week or less than 2 hours of structured exercise per week.

Exclusion criteria

Exclusion Criteria:

  • Presenting any pathology that could impede the correct performance of the tests, or could influence the main study variables.
  • In the case of the female sample, having irregular menstrual cycles, oligomenorrhea or amenorrhea.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Intervallic submaximal test

    Intervallic exercise test

    Other: Intervallic submaximal exercise test

Interventions

  • OtherIntervallic submaximal exercise test

    Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.

    Also known as: Interval exercise training

06

What researchers measure

Primary outcomes

  1. Plasma-Erythrocyte lactate difference

    Difference between lactate concentration inside the erythrocytes and lactate concentration in plasma, expressed in mMol/L (Millimoles Per Liter), from venous blood extracted during the intervallic test from the antecubital vein.

    Time frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years

  2. Level of Monocarboxylate Transporter 1 in erythrocytes membrane

    Protein abundance of the monocarboxylate transporter 1 in erythrocyte membranes. It is measured using flow cytometry, from venous blood extracted from the forearm in rest state.

    Time frame: Through study completion, average of 5 years, an average of 2 months per participant

Secondary outcomes

  1. Erythrocyte lactate concentration

    Lactate concentration inside the erythrocytes, expressed in mMol/L (Millimoles Per Liter), measured in erythrocytes extracted from processed venous blood. Lactate concentration is measured in the supernatant obtained after the lysis and centrifugation of the solid part of the blood (mainly erythrocytes), separated by centrifugation. Venous blood samples are extracted during the intervallic test from the antecubital vein.

    Time frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years

  2. Plasma lactate concentration

    Lactate concentration, expressed in mMol/L (Millimoles Per Liter), measured in the plasma of centrifugated venous blood, using a lactate analyzer. Lactate concentration is measured in the plasma obtained from venous blood extracted during the intervallic test from the antecubital vein.

    Time frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years

  3. Blood lactate concentration

    Lactate concentration, expressed in mMol/L (Millimoles Per Liter), measured from whole venous blood extracted during the intervallic test from the antecubital vein.

    Time frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years

  4. Blood pH

    Level of blood pH measured in venous blood extracted during the intervallic test from the antecubital vein.

    Time frame: Through Phase I of the project, only in the intervallic submaximal test. Average of 3 years

Other outcomes

  1. Genotype for the rs1049434 polymorphism of the SLC16A1 (MCT1) gene

    Genotype for the Asp490Glu (T1470A) (rs1049434) polymorphism of the SLC16A1 (MCT1) gene, resulting in one of the following three profiles: TT (Arg/Arg), TA (Arg/Glu) or AA (Glu/Glu)

    Time frame: Through sample recruitment, average of 5 years, an average of 1 month per participant

  2. Physical Activity level

    The IPAQ self-reported questionnaire will be used to quantify physical activity levels.

    Time frame: Through sample recruitment, average of 5 years, an average of 1 month per participant

07

Study locations

2 of 2 sites recruiting
  • Laboratorio de Pediatría. School of Medicine. Univesidad de Cantabria
    Santander, Cantabria 39011, Spain
    Recruiting
    • Teresa Amigo · Contactteresa.amigo@unican.es
    • Domingo González-Lamuño, PhD · Principal investigator
    • Teresa Amigo · Sub investigator
  • Laboratorio de Fisiología del Esfuerzo. Facultad de Ciencias de la Actividad Física y del Deporte (INEF). Universidad Politécnica de Madrid
    Madrid, Madrid 28040, Spain
    Recruiting
    • Ildefonso Fernández · Contactlaboratorio.fisiologia.inef@upm.es · +34910677866
    • Rocío Cupeiro, PhD · Contactrocio.cupeiro@upm.es · +34910677990
    • Rocío Cupeiro, PhD · Principal investigator
    • Jose A Benítez-Muñoz, MS · Sub investigator
    • Jacobo Á Rubio, PhD · Sub investigator
    • Pedro J Benito, PhD · Sub investigator
    • Miguel A Rojo-Tirado, PhD · Sub investigator
08

References and documents

Publications

  • Benitez-Munoz JA, Rojo-Tirado MA, Benito Peinado PJ, Murias JM, Gonzalez-Lamuno D, Cupeiro R. Greater Relative First and Second Lactate Thresholds in Females Compared With Males: Consideration for Exercise Prescription. Int J Sports Physiol Perform. 2024 Oct 28;20(1):30-36. doi: 10.1123/ijspp.2024-0079. Print 2025 Jan 1. PubMed 39467538 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Jun 2027, 88 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 88 months is above that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 27, 2023
StartActual
Feb 3, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104150
Lead sponsor
Technical University of Madrid
Responsible party
Rocío Cupeiro, PhD (Physical Activity and Sports PhD (Associate Professor), Technical University of Madrid) — Principal investigator
First posted
Oct 27, 2023
Start date
Feb 3, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Rocío Cupeiro, PhD
Contact
rocio.cupeiro@upm.es
+34910677990
Rocío Cupeiro, PhD
principal investigator · Universidad Politecnica de Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion